Results 131 to 140 of about 25,818 (186)

Case Report: HGF and NF1 mutations as putative bypass mechanisms of MET inhibitor resistance in hepatocellular carcinoma: a case study. [PDF]

Front Pharmacol
Chen Z, Luo S, Gu Y, Li Q.
europepmc   +1 more source

Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances. [PDF]

Cancers (Basel)
Deng F, Ma W, Wei S.
europepmc   +1 more source

Durable response with mutation-guided <i>ALK</i> inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case report. [PDF]

Rare Tumors
Chaudhry SS, Camidge DR, Clay MR, Wilky BA.   +3 more
europepmc   +1 more source

Case Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib. [PDF]

Front Oncol
Ye W, Li P, Fu C, Zhou T.
europepmc   +1 more source

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review. [PDF]

Curr Oncol
Bischoff H, Gendarme S, Somme L, Chouaid C, Schott R.   +4 more
europepmc   +1 more source

Real-World Outcomes of Brigatinib Compared to Alectinib as a Second-Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients. [PDF]

Thorac Cancer
Kim MJ, Kwak HS, Koh EN, Park CK, Kim YC, Oh IJ, Kim SJ, Lim JH, Ryu JS, Choi CM.   +9 more
europepmc   +1 more source

An updated review on systemic therapy for brain metastases in non-small cell lung cancer. [PDF]

Transl Cancer Res
Louis S, Aboubechara JP, Saigal K, Cao T, Nagpal S.   +4 more
europepmc   +1 more source

Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models. [PDF]

J Med Chem
Sharkawy S, Acharya S, Kostrhunová H, Maji M, Marková L, Novohradský V, Gibson D, Brabec V.   +7 more
europepmc   +1 more source

Innovative inhalable dry powder: nanoparticles loaded with Crizotinib for targeted lung cancer therapy. [PDF]

BMC Cancer
Naureen F, Shah Y, Rehman MU, Fazli Nasir FN, Pirzada AS, Al-Otaibi JS, Daglia M, Khan H.   +7 more
europepmc   +1 more source

Combining mechanistic quantitative systems pharmacology modeling and patient-derived organoid testing in MET-aberrant non-small cell lung cancer for high-throughput combination efficacy analysis and personalized treatment design. [PDF]

Front Pharmacol
Hu J, Zhao Y, Rao Q, Li G, Jiao Z, Wang H, Qu Y, Xu S, Gu Z, Wang T, Chen Z, Zhao C, Zhou G.   +12 more
europepmc   +1 more source